07-04-2008: Photocure has been awarded NOK 9.1 million for the next three years from The Research Council of Norway (RCN) high-profile programme "User-driven Research-based Innovation" (BIA). Photocure received the grant for the project "Early detection of premalign conditions in colon when using fluorescence colonoscopy".
In this project, Photocure will develop fluorescence-based photodynamic diagnosis to improve detection of tumors compared to standard colonoscopy in patients with suspicion of colorectal cancer. The grant will be used to develop an oral formulation of the compound hexylaminolevulinate and fund clinical studies in the development program.
Kjetil Hestdal MD. Ph.D., President and CEO of Photocure comments: "The grant from the RCN is important for the development of the colon project. The current grant will give Photocure financial support through this first, crucial phase of the development of the drug formulation and clinical studies. The RCN's BIA program is vital for innovative projects like the colon fluorescence project. In addition to the financial implications of the grant, I am pleased to register that the independent evaluators of the RCN share our belief in the photodynamic technology."
This is where you can add this news to your personal favourites
Photocure ASA announced the appointment of Erik Dahl to its management team as the Chief Financial Officer, effective 15 August 2012.Dahl joins Photocure with more than 20 years of experience in senior level financial management roles in both international public and private companies. He h ... more
Photocure ASA announced the results of the phase 2b study in acne with Visonac (methyl aminolevulinate 80mg/g), a topical acne treatment. In this study, Visonac showed a statistically significant reduction in inflammatory lesions and overall improvement in acne severity.The phase 2b trial ... more
Photocure ASA announced the achievement of the second manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix worldwide, excluding the US and Nordic region. This triggers a payment of EUR 1.5 million. Hexvix is Photocure’s flagship product to aid ... more
Photocure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange (PHO). The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology, targeting key dermatology and oncology markets. more
More about Research Council of Norway
The Research Council of Norway
Photocure has been awarded NOK 9.1 million for the next three years from The Research Council of Norway (RCN) high-profile programme "User-driven Research-based Innovation" (BIA). Photocure received the grant for the project "Early detection of premalign conditions in colon when using fluor ... more
The Research Council is divided into five divisions: Science, Energy, Resources and the Environment, Society and Health, Innovation and Administration. The Executive Board is the Research Council's highest authority. more